🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

James Waisman

ORCID: 0000-0003-2896-4146

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer”.

PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101420

N/A

1.9DataRank · unranked

110 citations

Weihua Guo, Guo Zhikun, Jiangnan Yu, Jiayi Tan, Diana L. Simons +9 more

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002084

N/A

1.3DataRank · unranked

32 citations

Weihua Guo, Susan E. Yost, Jin Sun Lee, D. L. ROSE, Christian Avalos +7 more

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03470-y

N/A

0.809DataRank · unranked

22 citations

Weihua Guo, Susan E. Yost, Xuan Ge, Jin Sun Lee, Paul Frankel +12 more

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

The Oncologist(2023)10.1093/oncolo/oyad026

N/A

0.580DataRank · unranked

14 citations

Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang +10 more

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer

The Oncologist(2020)10.1002/onco.13574

N/A

0.568DataRank · unranked

43 citations

Jin Sun Lee, Susan E. Yost, Sierra Min Li, Paul Frankel, Christopher Ruel +17 more

Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.02.020

N/A

0.430DataRank · unranked

7 citations

Jin Sun Lee, Susan E. Yost, Tracey Stiller, M. Suzette Blanchard, Simran Padam +13 more

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

Cancers(2022)10.3390/cancers14174279

N/A

0.385DataRank · unranked

12 citations

Susan E. Yost, Jin Sun Lee, Paul Frankel, Christopher Ruel, Yujie Cui +13 more

Organ-Specific Immune Setpoints Underlie Divergent Immune Profiles across Metastatic Sites in Breast Cancer

Cancer Immunology Research(2024)10.1158/2326-6066.cir-23-0718

N/A

0.208DataRank · unranked

3 citations

Weihua Guo, Diana L. Simons, Jian Ye, Christian Avalos, Shawn T. Solomon +10 more

Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.1060

N/A

0DataRank · unranked

2 citations

Carolyn E. Behrendt, Susan E. Yost, Niki Patel, Raynald Samoa, Daphne Stewart +6 more

Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer

Journal of Clinical Medicine(2023)10.3390/jcm12051906

N/A

0DataRank · unranked

4 citations

Sayeh Lavasani, Leon Cristobal, Niki Tank Patel, Mina S. Sedrak, Daphne Stewart +10 more

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

Breast Cancer(2023)10.1007/s12282-023-01473-2

N/A

0DataRank · unranked

7 citations

Carolyn E. Behrendt, Saro Kasparian, Tina Nguyen, Mina S. Sedrak, Sayeh Lavasani +7 more

Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer

JCI Insight(2022)10.1172/jci.insight.153963

N/A

0DataRank · unranked

47 citations

Weihua Guo, Jiayi Tan, Christian Avalos, Diana L. Simons, Min Hui Lim +13 more

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan

Cancer Medicine(2024)10.1002/cam4.70096

N/A

0DataRank · unranked

14 citations

Veronica Jones, Wai Yu, Linda D. Bosserman, Sayeh Lavasani, Niki Patel +6 more

Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes

EBioMedicine(2020)10.1016/j.ebiom.2020.102631

N/A

0DataRank · unranked

84 citations

Diana L. Simons, Xuyang Lu, Travis Y. Tu, Christian Avalos, Andrew Y. Chang +5 more